# Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

> **NCT05529069** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Mantle Cell Lymphoma
- Non Hodgkin Lymphoma
- Hematologic Malignancy

## Interventions

- **DRUG:** Pirtobrutinib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05529069
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-25
- **Primary completion:** 2027-04-28
- **Final completion:** 2027-04-28
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05529069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05529069, "Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05529069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*